跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RIVASTIGMINE PATCH 5 - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RIVASTIGMINE PATCH 5
Authorized
STANDARD
RIVASTIGMINE PATCH 5
Pharmascience Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
76435e4743a4307f
Company
Pharmascience Inc
Type
Standard
Approval Details
Approval Id
76435e4743a4307f
Drug Approval Canada Name
RIVASTIGMINE PATCH 5
Product Name
RIVASTIGMINE PATCH 5
Status
Dormant
Status Date
2024-07-31
Original Market Date
2021-04-15
Din
02479540
Drug Class
Human
Dosage Form
Patch
Route Of Administration
Transdermal
Schedule
Prescription
Ahfs
12:04.00
Atc Original
N06DA03 RIVASTIGMINE
Atc Name
n 06 da 03
Aig Number
0140521007
Company Name
Pharmascience Inc
Company Address
100, 6111 Royalmount Ave, Montreal, Quebec, Canada, H4P 2T4
Company Detail Path
/organization/pharmascience-inc
Company Information
Pharmaceutical Company Name
Pharmascience Inc
Country Name
Canada
Province Name
Quebec
City Name
montréal,quebec,country_ca
Address
6111 av Royalmount bureau 100
Active Ingredients
RIVASTIGMINE
4.6 MG / 24 HOUR
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
76435e4743a4307f
Type
Standard
Back to Health Canada Approvals